Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

Yoshihiko Sakata; Go Saito; Shinya Sakata; Yuko Oya; Motohiro Tamiya; Hidekazu Suzuki; Ryota Shibaki; Asuka Okada; Toshihide Yokoyama; Hirotaka Matsumoto; Taiichiro Otsuki; Yuki Sato; Uchida Junji; Yoko Tsukita; Megumi Inaba; Hideki Ikeda; Daisuke Arai; Hirotaka Maruyama; Satoshi Hara; Shinsuke Tsumura; Jun Morinaga; Takuro Sakagami

doi:10.1016/j.lungcan.2023.107450

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Uchida Junji, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke TsumuraJun Morinaga, Takuro Sakagami

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

抄録

The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.

本文言語	英語
論文番号	107450
ジャーナル	Lung Cancer
巻	188
DOI	https://doi.org/10.1016/j.lungcan.2023.107450
出版ステータス	出版済み - 02-2024
外部発表	はい

All Science Journal Classification (ASJC) codes

腫瘍学
呼吸器内科
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.lungcan.2023.107450

他のファイルとリンク

フィンガープリント

「Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Sakata, Y., Saito, G., Sakata, S., Oya, Y., Tamiya, M., Suzuki, H., Shibaki, R., Okada, A., Yokoyama, T., Matsumoto, H., Otsuki, T., Sato, Y., Junji, U., Tsukita, Y., Inaba, M., Ikeda, H., Arai, D., Maruyama, H., Hara, S., ... Sakagami, T. (2024). Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). Lung Cancer, 188, 記事 107450. https://doi.org/10.1016/j.lungcan.2023.107450

Sakata, Yoshihiko ; Saito, Go ; Sakata, Shinya その他. / Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). In: Lung Cancer. 2024 ; Vol. 188.

@article{2d538eece07f42d6922f11e24e6fa809,

title = "Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))",

abstract = "The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.",

author = "Yoshihiko Sakata and Go Saito and Shinya Sakata and Yuko Oya and Motohiro Tamiya and Hidekazu Suzuki and Ryota Shibaki and Asuka Okada and Toshihide Yokoyama and Hirotaka Matsumoto and Taiichiro Otsuki and Yuki Sato and Uchida Junji and Yoko Tsukita and Megumi Inaba and Hideki Ikeda and Daisuke Arai and Hirotaka Maruyama and Satoshi Hara and Shinsuke Tsumura and Jun Morinaga and Takuro Sakagami",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2024",

month = feb,

doi = "10.1016/j.lungcan.2023.107450",

language = "English",

volume = "188",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Sakata, Y, Saito, G, Sakata, S, Oya, Y, Tamiya, M, Suzuki, H, Shibaki, R, Okada, A, Yokoyama, T, Matsumoto, H, Otsuki, T, Sato, Y, Junji, U, Tsukita, Y, Inaba, M, Ikeda, H, Arai, D, Maruyama, H, Hara, S, Tsumura, S, Morinaga, J & Sakagami, T 2024, 'Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))', Lung Cancer, vol. 188, 107450. https://doi.org/10.1016/j.lungcan.2023.107450

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). / Sakata, Yoshihiko; Saito, Go; Sakata, Shinya その他.
In: Lung Cancer, Vol. 188, 107450, 02.2024.

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

TY - JOUR

T1 - Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

AU - Sakata, Yoshihiko

AU - Saito, Go

AU - Sakata, Shinya

AU - Oya, Yuko

AU - Tamiya, Motohiro

AU - Suzuki, Hidekazu

AU - Shibaki, Ryota

AU - Okada, Asuka

AU - Yokoyama, Toshihide

AU - Matsumoto, Hirotaka

AU - Otsuki, Taiichiro

AU - Sato, Yuki

AU - Junji, Uchida

AU - Tsukita, Yoko

AU - Inaba, Megumi

AU - Ikeda, Hideki

AU - Arai, Daisuke

AU - Maruyama, Hirotaka

AU - Hara, Satoshi

AU - Tsumura, Shinsuke

AU - Morinaga, Jun

AU - Sakagami, Takuro

PY - 2024/2

Y1 - 2024/2

N2 - The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.

AB - The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.

UR - http://www.scopus.com/inward/record.url?scp=85181238201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181238201&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2023.107450

DO - 10.1016/j.lungcan.2023.107450

M3 - Comment/debate

C2 - 38160082

AN - SCOPUS:85181238201

SN - 0169-5002

VL - 188

JO - Lung Cancer

JF - Lung Cancer

M1 - 107450

ER -

Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H その他. Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). Lung Cancer. 2024 2月;188:107450. doi: 10.1016/j.lungcan.2023.107450